Dr Namrata TRUE TALES OF TEN T-PLL OVER A DECADE

  • Dr Namrata.N. Rajakumar kidwai memorial institute of oncology
  • Dr Raghavendra .H. Vijaya kidwai memorial institute of oncology
  • Dr laxmi B Horatti Shri Atal Bihari Vajpayee Medical college and Research center
  • Dr Girish Balikai SDM college of medical sciences and hospital
  • Dr Murugesh Shamnur JJM Medical college Davangere
Keywords: T -prolymphocytic leukemia, immunophenotyping; T-leukemias.flow cytometry,Next generation sequencing

Abstract

Background

T- prolymphocytic leukemia(T-PLL) ,are aggressive lymphoid malignancies with unique morphologic, cytogenetic, immunophenotypic, and molecular features. T-PLL is a mature T-cell leukemia typically presenting at stages of exponentially rising lymphocyte counts in peripheral blood,accompanied by splenomegaly and bone marrow involvement. They are extremely rare  ,comprising of <2% of  mature T –leukemias and inherently aggressive and notoriously refractory to therapeutics.Extensive  search for Indian literature on T-PLL and  Immunophenotypic characterization of this entity did not yield any results. We analysed the characteristics, prognostic factors, outcomes and treatments of 10 patients with T-PLL . To our knowledge this is  the largest series of T-PLL from India , this study reviews clinical, cytogentic and flow cytometric immunophenotyping  findings, and differential diagnosis  of patients with T-cell prolymphocytic leukemia from January 2012 to January 2022.Methods: Our laboratory received 4500  clinically  suspected chronic leukemias, during a period of 10 years ,at kidwai memorial institute of oncology ,which is state cancer institute , where  diagnostic flow cytometric analysis was done and leukemias were classified based on WHO  2008 criterias.  Results: out of 4500 cases of Chronic lympho proliferative disorders sent for flow cytometric immunophenotyping, only 10 cases were  diagnosed as T-PLL .Study period January 2012 to January 2022.Conclusions: Evaluation of immunophenotype  of this  rare entity by flow cytometry is a critical     part of  diagnosis and is a indespensible tool in distinguishing T-PLL from other mature T-cell lymphoid   neoplasms.Awareness of this rare entity aids in work up .

Downloads

Download data is not yet available.

Author Biographies

Dr Girish Balikai, SDM college of medical sciences and hospital

Professor and Head Hematooncology

Dr Murugesh Shamnur, JJM Medical college Davangere

 PROFESSOR AND HOD 

DEPATMENT OF DERMATOLOGY

References

1.D.Catovsky,H K Muller-Hermelink,E.Ralfkiaer et al. WHO Classfication of Tumors of Hematopoietic and Lymphoid Tissues.4 th edition. IARC,Lyon,France: 2008.pp270-71
• 2. Matutes E, Catovsky D, Mature T-cell leukemias and leukemia/ lymphoma syndromes. Review of our experience in 175 cases. Leuk Lymphoma 1991 ;volume 4: issue 2,81-91 https://doi.org/10.3109/10428199109068049
• 3. .P.Jain, E.Aoki , M.Keating et al. Characteristics, outcomes , prognostic factors and treatment of patients with T-cell pro lymphocytic leukemia (T -PLL). Annals of Oncology2017;Volume 28: 1554 – 1559. 10.1093/annonc/mdx163

• 4.Marco Herling, Joseph D Khoury, LaBaron T et al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 2004;volume 104:number 2:328-335 10.1182/blood-2004-01-0002
5.Xueyan Chen , Sindhu Cherian . Immuno phenotypic Characterization of T-Cell Pro lymphocytic Leukemia. Am J Clin Pathol 2013;140: 727-735 https://doi.org/10.1309/AJCPG71KYOXTKLQW
6.Pawson R, Matutes E , Brito-Babapulle V et al. Sezary cell leukaemia: a distinct T cell disorder or a variant form of T pro-lymphocytic leukaemia?.Leukemia 1997;11: 1009-1013 https://doi.org/10.1038/sj.leu.2400710
7.Matutes E, Brito-Babapulle V,Swansbury J et al.Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991;volume78: issue 12:3269-3274 https://doi.org/10.1182/blood.V78.12.3269.3269
8. Bain BJ, Barnett D, Linch D, Matutes E, Reily JT. Revised guideline on immuno phenotyping in acute leukemia and chronic lympho proliferative disorders.Clin.Lab.Haem2002;24:1-13 https://doi.org/10.1046/j.1365-2257.2002.00135.x
9.Shano Naseem. Ritu gupta,Rajesh kashyap et al .T-Cell pro lymphocytic leukemia;a report of 2 cases with review of literature .indian journal of hematology and blood transfusion 2008;24:178-181
10. Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell pro loymphocytic leukemia. Blood 2008; 111(1): 328-337 https://doi.org/10.1182/blood-2007-07-101519
11.Philipp B Staber, Marco Herling, Mar Bellido. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell pro lymphocytic leukemia. Blood. 2019 Oct 3; 134(14): 1132–1143. doi: 10.1182/blood.2019000402.
12. Dearden CE,Khot A, Else M, et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia:comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood 2011; 118(22):5799-5802. https://doi.org/10.1182/blood-2011-08-372854
13. Till Braun , Jana von Jan, Linus Wahnschaffe , et al. Advances and Perspectives in the treatment of T-PLL. Current Hematologic Malignancy Reports 2020:15(2):113-124. doi: 10.1007/s11899-020-00566-5
14. Alexandra Schrader , Till Braun and Marco Herling . The dawn of a new era in treating T-PLL . Oncotarget,2019;10: 626-628. https://doi.org/10.18632/oncotarget.26595
How to Cite
1.
Rajakumar DN, Vijaya DR .H., Horatti D laxmi B, Balikai DG, Shamnur DM. Dr Namrata TRUE TALES OF TEN T-PLL OVER A DECADE. Int J Med Res Rev [Internet]. 2023Nov.20 [cited 2024Dec.23];11(5):116-22. Available from: https://ijmrr.medresearch.in/index.php/ijmrr/article/view/1432
Section
Original Article